EMA Withdrawn: Rivastigmine Teva (rivastigmine) — Teva Pharma B.V.

View source ↗

Summary

The EMA withdrew Rivastigmine Teva (rivastigmine) from its European market authorization.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia
• Parkinson Disease

Drugs mentioned

• Rivastigmine Teva (rivastigmine)

Snippet

Status: Withdrawn. Therapeutic area: Dementia;Alzheimer Disease;Parkinson Disease. MAH: Teva Pharma B.V.. Decision date: 10/09/2012